Patients with retinal vein occlusion who received Vabysmo experienced visual improvements as well as extended treatment intervals at 72 weeks, according to a study. At Angiogenesis, Exudation, and ...
Ocular Therapeutix, Inc. has announced its participation in the Angiogenesis, Exudation, and Degeneration 2025 virtual meeting, scheduled for February 8, 2025, where it will present new findings ...
EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed every 4 ...
Findings highlight PL9654 and PL9655's potential to treat diabetic retinopathy through inflammation resolution, vascular stabilization, and neuroprotection PL9654 and PL9655 down-regulate inflammatory ...
The retina is inside the back of the eye, a multi-layered and vascular tissue, which receives light and transforms it to a neural impulse that goes to the brain. The optic nerve that transmits the ...
TARRYTOWN, N.Y., Feb. 08, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced the first presentation of positive results from the Phase 3 QUASAR trial investigating EYLEA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback